The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa).
A. K. Patel
No relevant relationships to disclose
L. J. Appleman
No relevant relationships to disclose
W. E. Gooding
No relevant relationships to disclose
D. Friedland
No relevant relationships to disclose
J. McKolanis
No relevant relationships to disclose
A. M. Salazar
Employment or Leadership Position - Oncovir
Stock Ownership - Oncovir
O. J. Finn
No relevant relationships to disclose
G. S. Chatta
No relevant relationships to disclose